Expression of astrocyte‐elevated gene‐1 indicates prognostic value of fluoropyrimidine‐based adjuvant chemotherapy in resectable stage III colorectal cancer

It is unclear which prognostic factor such as pathological features and gene mutation are majorly relevant for stage III disease and whether they aid in determining patients who will be benefit from postoperative adjuvant chemotherapy. The expression of astrocyte‐elevated gene‐1 (AEG‐1), thymidylate...

Full description

Saved in:
Bibliographic Details
Published in:Pathology international 2021-11, Vol.71 (11), p.752-764
Main Authors: Lin, Long‐Wei, Lai, Peng‐Sheng, Chen, Ying‐Yin, Chen, Chung‐Yu
Format: Article
Language:English
Subjects:
5-Fluorouracil
Adenocarcinoma - drug therapy
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Adenocarcinoma - surgery
adjuvant therapy
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
astrocyte‐elevated gene‐1
Biomarkers, Tumor - metabolism
Cancer
Cell Line, Tumor
Chemotherapy
Chemotherapy, Adjuvant
Colectomy
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - metabolism
Colorectal Neoplasms - pathology
Colorectal Neoplasms - surgery
Complementation
Epidermal growth factor
Epidermal growth factor receptors
ERCC1 protein
Female
Fluorouracil - therapeutic use
Gene expression
Growth factors
Humans
Male
Medical prognosis
Membrane Proteins - metabolism
Metastases
Middle Aged
Mutation
Neoplasm Staging
Patients
Point mutation
Prognosis
Regression analysis
Retrospective Studies
RNA-Binding Proteins - metabolism
Survival
Thymidylate synthase
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is unclear which prognostic factor such as pathological features and gene mutation are majorly relevant for stage III disease and whether they aid in determining patients who will be benefit from postoperative adjuvant chemotherapy. The expression of astrocyte‐elevated gene‐1 (AEG‐1), thymidylate synthase (TS), excision repair cross‐complementation group 1 (ERCC1), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) was examined to investigate their role in adjuvant chemotherapy for patients with resectable stage III colorectal cancer (CRC). A significant positive correlation was observed between AEG‐1, TS, ERCC1, EGFR, and VEGF gene expression levels in CRC cell lines, and low AEG‐1 and TS expression were highly sensitive to 5‐fluorouracil treatment. Our results showed that AEG‐1 expression was high in T4 and caused CRC recurrence or metastasis. Patients with T4, high AEG‐1, TS and VEGF expression had a significantly short disease‐free survival and overall survival. In multivariate Cox regression analysis, high AEG‐1 expression could be an independent prognostic factor indicating poor survival in patients with resectable stage III CRC treated with adjuvant chemotherapy. In conclusion, AEG‐1 expression and tumor grade are potential prognostic factors for recurrence and survival in patients with stage III CRC receiving adjuvant fluoropyrimidine‐based chemotherapy.
ISSN:1320-5463
1440-1827
DOI:10.1111/pin.13160